AbstractThe objective of this study was to evaluate the status of the counterfeit pharmaceuticals in Jordan. Four types of pharmaceuticals Lipitor (Atorvastatin-calcium), Concor (bisoprololfumarate), Co-Diovan (Valsartan, hydrochlorothiazide)and Plavix (clopidogrel) were subjected to physical and chemical analysis. 173 samples of these four medicines were collected from the three most populated cities in the country, namely Amman, the capital of Jordan, Zarqa and Irbid. A sample of confiscated counterfeited medicines was obtained from the health authorities and tested utilising the HPLC and dissolution testing, in order to validate the reliability of the testing procedures. Samples were then tested using High Performance Liquid Chromatography (HPLC) and dissolution tests in order to assess the quality of these samples.
Results of both chemical and physical analyses revealed that all samples were found to fall within the specification limits of United States Pharmacopoeia (USP) and no evidence was found of any counterfeit drug products in the samples examined. Since this study found no indication of a drug counterfeiting problem in Jordan, the researcher has concluded that there seemed to be two contributing factors to this result: first, the very effective legislative campaigns conducted by the health authorities’ in Jordan against counterfeit trade through new public health and pharmacy law which has been launched in 2008. Second, the rigorous tough enforcement measures conducted by health and law enforcement agencies in the country.
|Date of Award||2012|
|Supervisor||Andrew Reid (Supervisor) & Valerie Cox (Supervisor)|